Orthocell Reports Sixth Consecutive Quarter of Record Revenue in September Quarter
MT Newswires Live
Nov 06
Orthocell (ASX:OCC) said its revenue for the quarter ended Sept. 30 came in at $3 million, its highest result to date and the sixth consecutive quarter of record revenue, according to a Thursday Australian bourse filing.
Its revenue for the same period in the previous year was $2 million.
The firm is targeting inclusion in the ASX 300 index as part of its three-year vision. It seeks to advance its product pipeline with collagen scaffold applications in musculoskeletal repair, build a nerve repair portfolio, and validate advancements in cell therapy technology.
It is also focused on the launch of its Remplir nerve repair product in the US and Canada, as well as the onboarding of "strategic" countries in Asia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.